SRP3185

VEGF-D human

recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE), ≥95% (HPLC), suitable for cell culture

• Synonym(s): FIGF, Vascular Endothelial Growth Factor-D
• NACRES: NA.32
• UNSPSC Code: 12352202

Properties

• biological source: human
• recombinant: expressed in HEK 293 cells
• assay: ≥95% (HPLC), ≥95% (SDS-PAGE)
• form: lyophilized
• mol wt: 20.0-22.0 kDa
• packaging: pkg of 10 μg
• technique(s): cell culture | mammalian: suitable
• impurities: <0.1 EU/μg endotoxin, tested
• color: white
• UniProt accession no.: O43915

Description

General description

VEGFD (vascular endothelial growth factor D), or c-fos-induced growth factor, is a member of the VEGF family of growth factors, and is composed of VEGF-homology domain, receptor binding domains, and pro-peptides in both terminals. It is secreted in the extracellular space in a full length form with both C- and N-terminal pro-peptides, which are cleaved off to produce the mature VEGFD form. It is an angiogenesis-related factor.
Recombinant human VEGF-D is a 26.2 kDa non-disulfide linked homodimeric protein consisting of two 117 amino acid polypeptide chains. Due to glycosylation the protein migrates as a 20.0-22.0 kDa band under non-reducing condition.

Application

VEGFD (vascular endothelial growth factor D) human has been used in for the treatment of buffalo luteal cell culture to determine the effect of VEGFD on the expression of lymphatic endothelial marker (LYVE1), thereby investigating the role of VEGFD in luteal lymphangeogenesis during different stages of estrous cycle.

Biochem/physiol Actions

Mature VEGFD (vascular endothelial growth factor D) interacts with VEGFR-3, a tyrosine kinase receptor, with high affinity. This receptor predominantly resides on adult lymphatic endothelium and participates in lymphangiogenesis. VEGFD also interacts with Nrp-2 (neuropilin), a non-tyrosine kinase receptor, which functions as a lymphangiogenesis-associated factor. This factor promotes tumor lymphangiogenesis and hence, lymph node metastasis in various cancers, such as ovarian cancer. In patients with CRC (colorectal cancer), higher expression of VEGFD is linked with resistance to bevacizumab, and has potential as a biomarker for predicting the benefit of bevacizumab in CRC chemotherapy.

Physical form

Lyophilized with no additives.

Preparation Note

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Other Notes

FAATFYDIET LKVIDEEWQR TQCSPRETCV EVASELGKST NTFFKPPCVN VFRCGGCCNE ESLICMNTST SYISKQLFEI SVPLTSVPEL VPVKVANHTG CKCLPTAPRH PYSIIRR

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable